AstraZeneca Licenses Protherics Sepsis Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.